Infertility Drugs Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Infertility Drugs Market 

5.1. COVID-19 Landscape: Infertility Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Infertility Drugs Market, By Drug Class

8.1. Infertility Drugs Market Revenue and Volume, by Drug Class, 2024-2033

8.1.1 Gonadotropins

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Aromatase Inhibitors

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Selective Estrogen Receptor Modulators (SERMs)

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Dopamine Agonists

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Infertility Drugs Market, By Distribution Channel

9.1. Infertility Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033

9.1.1. Hospital Pharmacy

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Specialty & Retail Pharmacy

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Online Pharmacy

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Infertility Drugs Market, By End-user 

10.1. Infertility Drugs Market Revenue and Volume, by End-user, 2024-2033

10.1.1. Men

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Women

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Infertility Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)

Chapter 12. Company Profiles

12.1. Merck & Co., Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Ferring B.V.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Organon Group of Companies

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Abbott

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Novartis AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bayer AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Pfizer Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Mankind Pharma

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Teva Pharmaceutical Industries LTD.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Sanofi

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms